Roche persists; Ventana resists:
This article was originally published in Clinica
Executive Summary
Continuing its pursuit of Ventana Medical Systems, Roche has extended for the fourth time its offer for shares of the tissue-based diagnostics firm. The Swiss group is seeking to acquire Ventana for $75 per share - a proposal that the Tucson, Arizona company has steadfastly refused to accept - and has pushed the deadline for the tender offer to January 17 2008. So far, less than 0.2% of Ventana's 35 million outstanding shares have been tendered. Ventana's president and CEO Christopher Gleeson branded Roche's offer price as a -non-starter", as it did not reflect the company's full potential. The firm upped its revenue and earnings targets for 2007, after it saw its third-quarter sales jump 28% to reach $75.5m. Ventana attributed its top-line growth to its core advanced staining business gaining sales momentum and market share. The company now expects full-year revenue to be between $296-300m, and earnings to be around $1.34 per share.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.